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Abstract 
Purpose: To investigate the prognostic implications of plasma fibrinogen and serum C-reactive protein 
(CRP) levels in tumour resection and survival following successful tumour resection in patients with non-
small cell lung cancer (NSCLC). 
Methods: One hundred and fifty-three NSCLC patients who underwent surgical resection at a tertiary 
care hospital from January 2006 through December 2010 were enrolled. Pre-operative serum CRP and 
plasma fibrinogen levels were measured. The levels of these biomarkers correlated with tumour size 
and pathologic TNM stage. The possibility of complete resection and associated findings are reported.  
Results: Plasma fibrinogen (r = 0.381, p = 0.002) and serum CRP (r = 0.471, p < 0.001) levels were 
positively associated with tumour diameter. Increased levels of these biomarkers were significantly 
associated with sex, smoking status, histological type, tumour stage, and clinical stage. Partial tumour 
resection occurred in 28 % (27/95) of patients with an increased plasma fibrinogen level compared to 10 
% (6/58) with a normal fibrinogen level (p = 0.008), and in 30 % (29/97) of patients with an increased 
serum CRP level compared to 11 % (6/56) with a normal CRP level (p = 0.006). Patients with elevated 
CRP and fibrinogen concentrations demonstrated higher susceptibility to disease advancement and 
survival compared to patients with normal fibrinogen and CRP levels. 
Conclusion: Pre-operative functional concentrations of serum CRP and plasma fibrinogen could serve 
as indicators of tumour resectability wherein a high tumour resection rate is possible in patients with 
favourable pre-operative levels of these biomarkers. Increased concentrations of serum CRP and 
plasma fibrinogen are associated with poor overall survival and progression-free survival. 
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Lung cancer is the most frequently observed 
human malignancy worldwide [1]. The World 
Health Organisation (WHO) reported that lung 
cancer causes more than 1.6 million deaths 
annually; moreover, the stated overall 5-year 
survival rate following diagnosis is approximately 
15 % [1]. Non-small cell lung cancer (NSCLC) 
represents more than 85 % of all lung cancers 
[1]. Tumour resection has been the standard 
treatment for many years; however, more than 
60 % of NSCLC patients have metastatic or 
advanced tumours at initial presentation [2], 
which precludes surgical resection. A difficult-to-
operate malignant lung tumour with limited 
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metastasis detected before surgery can be made 
operable using pre-operative chemotherapy 
and/or radiotherapy [3]. However, in patients with 
inoperable tumours with widespread metastasis, 
palliative care may be given without surgery. 
Although several imaging modalities such as 
chest X-rays, computerised tomography (CT) 
scanning, and magnetic resonance imaging 
(MRI) can be used to evaluate lung tumours and 
operability, the specificity and sensitivity of these 
techniques differ amongst tumour types [4,5]. 
The costs associated with such procedures are 
also high. There is urgent need for a pre-
operative biochemical screening test that will aid 
in determining the operability of NSCLC. 
 
The concept of inflammation in cancer 
pathogenesis is well established [6]. Serum C-
reactive protein (CRP), a common and short-
term reactive substance produced by the liver, is 
elevated in a number of chronic inflammatory 
illnesses, including cancer [6]. Possible 
mechanisms of elevated serum CRP levels in 
cancer may be due to tumour growth, the 
immune response to the tumour, and increased 
inflammatory cytokine production by tumour cells 
[7]. Serum CRP is elevated in several tumours, 
including lung cancers, and its relationship with 
prognosis has been evaluated in advanced 
NSCLC [8] and in resectable disease [9]. 
However, there are several disagreements in the 
few studies that have evaluated the relationships 
between CRP level, tumour size, and survival in 
patients with NSCLC [10]. There may also be a 
relationship between coagulation and 
malignancy. Hyperfibrinogenemia has been 
demonstrated in colorectal [11], cervical, 
oesophageal [12], and pancreatic cancers [13]. 
In NSCLC, hyperfibrinogenemia is associated 
with T-stage disease and tumour volume [14]. 
However, the usefulness of plasma fibrinogen 
concentrations in evaluating patients with 
resectable/non-resectable tumours, as well as in 
predicting the survival of NSCLC patients, is still 
under debate [15].  
 
To address these issues, we performed a 
prospective investigation to examine the 
relationships between serum CRP and plasma 
fibrinogen levels and tumour size in patients with 
NSCLC and determined the prognostic 
importance of these biomarkers in survival 






This prospective study was conducted with 
newly-diagnosed operable NSCLC patients 
enrolled between January 2006 and December 
2010. NSCLC patients previously suffering or 
showing coexistence of any cancer apart from 
NSCLC, treated by radiotherapy or 
chemotherapy, or with other diseases suspected 
of influencing serum CRP or plasma fibrinogen 
concentrations were excluded. A total of 153 
patients were enrolled at a tertiary hospital in 
China. The hospital’s Institutional Review Board 
sanctioned all ethical permissions (Approval No. 
2006/28020439) prior to inception of the study. 
Moreover, Council for International Organizations 
of Medical Sciences guidelines were adapted 
whilst dealing with human subjects [16]. Written 
consent was obtained from all participants.  
 
The patients were thoroughly evaluated prior to 
surgery based on their demographics, detailed 
pathological history, physical observations, and 
general laboratory testing. Lung cancer staging 
was performed according to TNM classifications 
based on the revised staging system of the 
International Association for the Study of Lung 
Cancer (IASLC) by evaluating chest X-ray and 
CT scans. The maximum tumour diameter was 
also estimated and recorded [17].  
 
An accurate evaluation of distant metastases 
was performed with bone scintigraphy, brain 
MRI, and an abdominal CT scan. In patients 
suspected of having N2-N3 disease, cervical 
mediastinoscopy was performed. The final 
histologic diagnosis of each case was based on 
the stratification for lung cancer established by 
the WHO and IASLC [18]. 
 
Surgery was performed on all study patients, 
and, depending on the location and size of the 
tumour, lobectomy, bilobectomy, 
segmentectomy, or pneumonectomy was 
performed. Post-surgery, some patients received 
adjuvant chemotherapy, adjuvant radiotherapy, 
or radiochemotherapy when indicated.  A 
standardised follow-up visit was conducted every 
3 months for 2 years, then every 6 months for the 
third year and annually thereafter. During each 
follow-up visit, a detailed physical observation, 
full blood count, chest CT, brain MRI, and 
abdominal ultrasound were performed. 
 
Patients received follow-up care from 1 to 48 
months with a median of 23 months. During the 
follow-up period, some of the patients relapsed, 
had a distant metastasis (or both), and/or died.  
Progression-free survival (PFS) was calculated 
as the time from surgery to local or distant 
tumour progression. Overall survival (OS) was 
calculated as the time from surgery until the time 
of death or final follow-up.  
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Serum CRP and fibrinogen measurements 
 
Blood samples from histologically confirmed 
NSCLC patients were collected by peripheral 
venous puncture. For serum CRP analysis, blood 
samples were collected in serum separator tubes 
and centrifuged at 1000 x g for 10 min at 4 oC. 
CRP levels were measured by routine clinical 
laboratory test protocols using an automatic 
nephelometer according to the manufacturer’s 
instructions (Beckman Coulter Inc., Fullerton, 
CA, USA). Plasma samples for fibrinogen 
analysis were separated by centrifuging blood 
samples collected in EDTA tubes at 1500 x g for 
15 min at 4˚C. Fibrinogen levels were measured 
using a clotting assay on an automated blood 
coagulation analyser (CA-7000; Sysmex Corp., 
Kobe, Japan) with thrombin reagent. All plasma 
and serum samples were stored at -80 oC in 
Eppendorf tubes prior to analysis and were 
analysed on the same day. A plasma fibrinogen 
concentration < 4.0 g/L was considered normal 
and a concentration ≥ 4.0 g/L was considered as 
hyperfibrinogenemic. A normal serum CRP level 
was defined as ≤ 0.8 mg/dL according to the 
manufacturer’s manual. However, on the basis of 
clinical relevance [17], a second cut-off value of 




Statistical calculations were performed using 
SPSS (version 17.0; SPSS Inc., Chicago, IL, 
USA). Categorical variables were summarised as 
proportions and compared using the chi-squared 
test. The relationships between the average 
serum CRP and plasma fibrinogen levels and 
clinicopathological variables were compared 
using the Kruskal-Wallis test, whilst Spearman’s 
rank correlation coefficient was employed to 
assess the correlation between maximum tumour 
diameter and plasma fibrinogen and serum CRP 
concentrations. PFS and OS were determined by 
a Cox proportional hazards regression analysis. 






The present investigation enrolled 153 patients 
who were suffering from NSCLC. The 
demographic and clinical characteristic features 
of the patients involved are shown in Table 1. 
The patients had a median age of 61 years, 
ranging from 35 to 81 years; 109 (71 %) were 
male and 44 (29 %) were female. On the basis of 
WHO/IASLC stratification criteria for lung 
cancers, 78 tumours (51 %) were histologically 
diagnosed as adenocarcinoma, 68 (44 %) as 
squamous cell carcinoma, 5 (3.3 %) as large cell 
carcinoma, and 2 (1.3 %) as other. A total of 92 
patients were smokers (ever/current) (60.1 %). 
Clinical staging performed according to the new 
IASLC criteria revealed that 64 (42 %) patients 
had stage I, 41 (27%) had stage II, 42 (27.5%) 
had stage III, and 6 (3.9%) had stage IV tumours. 
Overall, 112 (72%) patients underwent a 
lobectomy whilst the others underwent 
bilobectomy, segmentectomy, or 
pneumonectomy (Table 1). 
 
Table 1: Demographic and clinical charac-
teristics of the patients (N = 153) 
 
Variable Patients, N (%) 
Sex  
Male 109 (71.2) 
Female 44 (28.8) 
  
Age (years)  
< 65 104 (68.0) 
≥ 65 49 (32.0) 
  
Smoking  
Smoker 92 (60.1) 
Non-smoker  61 (39.9) 
  




Adenocarcinoma 78 (51.0) 
Large cell carcinoma 5 (3.3) 





T1 14 (9.2) 
T2 113 (73.8) 
T3 15 (9.8) 
T4 11 (7.2) 
  
Pathologic lymph node 
factor 
 
N0 84 (54.9) 
N1 40 (26.1) 
N2 29 (19.0) 
  
Clinical stage  
I 64 (41.8) 
II 41 (26.8) 
III 42 (27.5) 
IV 6 (3.9) 
  
Type of resection  
Pneumonectomy 22 (14.3) 
Bilobectomy 16 (10.5) 
Lobectomy 112 (73.2) 
Segmentectomy 3 (2.0) 
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Serum CRP and plasma fibrinogen 
concentrations 
 
We observed a median serum CRP 
concentration amongst all patients of 
approximately 4.86 mg/L (range: 0.67–128.46 
mg/L) and a median plasma fibrinogen level of 
3.53 g/L (range: 1.64–9.67 g/L). These two 
biomarkers were markedly correlated with sex, 
smoking status, histological type, tumour stage, 
and clinical stage. Higher levels of serum CRP 
and plasma fibrinogen were correlated with 
squamous cell carcinoma (p ≤ 0.001 and 0.001, 
respectively) compared to non-squamous cell 
carcinoma, and with pathological tumour stage (p 
= 0.001 and < 0.001, respectively) (Table 2). 
Spearman’s correlation coefficient established a 
positive correlation between maximum 
pathological tumour diameter and serum CRP 
level (r = 0.471, p < 0.001) (Fig. 1). The scatter 
plot in Fig. 2 also reveals that plasma fibrinogen 
concentration and maximum pathologic tumour 
volume were positively associated (r = 0.381, p = 
0.002). Moreover, the serum concentrations of 
both biomarkers (CRP and fibrinogen) were 
positively associated with each other (r = 0.410, 
p < 0.001). Overall, 62% (95/153) of the patients 
had an elevated serum fibrinogen (> 4 g/L) level 
compared to 38% (58/153) with a normal level. 
Additionally, approximately 63% (97/153) of 
patients had an increased serum CRP (> 20 




Figure 1: Scatter plot showing the correlation between serum CRP level and maximum tumour size 
   
 
Figure 2: Scatter plot showing the correlation between plasma fibrinogen level and maximum tumour 
size  
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Table 2: Serum C-reactive protein (CRP) and plasma fibrinogen levels according to clinicopathological 
parameters in patients with non-small cell lung cancer 
 
Factor Serum CRP (mg/L) Plasma fibrinogen (g/L) 
Median p Median p 
Sex  0.001  < 0.001 
Male 5.06  3.72  
Female 4.81                                                                                                                          3.39  
     
Age (years)  0.39  0.46 
< 65 4.77  3.42  
≥ 65 4.98  3.81  
     
Smoking  0.001  0.002 
Smoker 4.79  3.71  
Non-smoker 4.62  3.29  
     
Histology  < 0.001  0.001 
Squamous cell carcinoma 5.04  3.97  
Adenocarcinoma 4.48  3.25  
Large cell carcinoma 4.37  3.28  
Other 4.77  3.41  
     
Tumour factor  0.001  < 0.001 
T1 4.40  3.08  
T2 4.82  3.47  
T3 5.73  4.49  
T4 5.02  3.77  
     
Lymph node factor  0.093  0.061 
N0 4.76  3.41  
N1 4.97  3.67  
N2 4-89  3.59  
     
Clinical stage  < 0.001  0.001 
I 4.78  3.45  
II 4.96  3.64  
III 4.85  3.70  
IV 4.98  3.75  
 
Tumour resection and levels of serum CRP 
and fibrinogen 
 
Incomplete tumour resection occurred in 28% 
(27/95) of patients with an elevated plasma 
fibrinogen level (> 4 g/L) compared to only 10% 
(6/58) with a normal fibrinogen (≤ 4 g/L) level (p 
= 0.008), and in 30% (29/97) of patients with a 
serum CRP > 20 mg/L compared to only 11% 
(6/56) with a CRP level ≤ 20 mg/L (p = 0.006). 
This combined analysis indicates that when 
either the plasma fibrinogen level was ≤ 4 g/L or 
the CRP level was ≤ 20 mg/L, only 10% (10/99) 
of patients had an incomplete resection, which is 
quite low compared to 28% (15/54) of patients 
with a plasma fibrinogen level > 4 g/L and a 
serum CRP level > 20 mg/L (p = 0.005).  
 
Correlations between serum CRP and 
fibrinogen levels and survival 
 
The estimated 3-year PFS and OS rates were 60  
 
and 79%, respectively. These survival rates were 
inversely proportional to the plasma fibrinogen 
and serum CRP concentrations. Compared to 
patients with a normal serum fibrinogen level, 
patients with hyperfibrinogenemia exhibited lower 
3-year PFS (42.8 vs. 73.6%) and OS (56.0 vs. 
80.9%) rates. Similarly, compared to patients 
with a normal serum CRP level, patients with an 
elevated serum CRP level had lower 3-year PFS 
(46.2 vs. 71.2%) and OS (52.0 vs. 76.4%) rates. 
 
A significantly higher survival rate was observed 
in patients with a stage I or II tumour who had a 
serum CRP level ≤ 20 mg/L and a plasma 
fibrinogen level ≤ 4 g/L compared to those with 
CRP and fibrinogen values higher than the 
abovementioned values (p < 0.001). A univariate 
analysis revealed that post-resection, OS was 
significantly related to age, clinical T and N 
category, cancer stage, and the type of resection 
procedure (Table 3). Cox proportional hazards 
regression analysis revealed that plasma  
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Table 3: Relationships between patient characteristics and post-operative overall survival 
 
Variable Median duration 
(months) 
p 
Sex Male:Female  29:28 0.214 
Age (years) ≤ 65:≥ 66 32:26 0.031 
Smoking Smokers:Non-smokers 28:27 0.189 
Stage I:II:III:IV 34:30:26:18 < 0.00  1 
Tumour factor T1:T2:T3 33:28:21 0.032 
Histology* Squamous:Non-squamous 28:27 0.284 
Lymph node factor  N0:N1, N2  34:31:25 < 0.001 
Resection Lobectomy, bilobectomy:Pneumonectomy 30:23:16 < 0.001 
*Squamous cell carcinoma:Non-squamous cell carcinoma (adenocarcinoma, large cell carcinoma, 
and other) 
 
Table 4: Associations between serum C-reactive protein (CRP) and plasma fibrinogen levels and patient 
survival# 
 
Patient survival Crude HR 95% CI p Adjusted HR 95% CI p 
Progression-free survival       
Serum CRP concentration (< 20 mg/L) 1   1   
Serum CRP concentration (> 20 mg/L)* 1.53 1.1–2.1 0.004 1.31 1.05–2.2 0.01 
Plasma fibrinogen concentration (< 4 g/L) 1   1   
Plasma fibrinogen concentration (> 4 g/L) 1.49 1.1–2.2 0.005 1.44 1.09–2.13 0.004 
       
Overall survival       
Serum CRP concentration (< 20 mg/L) 1   1   
Serum CRP concentration (> 20 mg/L) * 2.06 1.3–3.1 0.001 1.72 1.20–2.66 0.005 
Plasma fibrinogen concentration (< 4 g/L) 1   1   
Plasma fibrinogen concentration (> 4 g/L) * 2.12 1.5–3.2 0.002 1.65 1.38–3.62 0.017 
#Association determined by Cox proportional hazards regression; adjusted for age, sex, smoking status, stage, 
grade, and histological type. *Hazard ratio (HR) calculated with respect to normal biomarker levels. A p-value < 
0.05 was considered statistically significant. CI, confidence interval 
 
fibrinogen and serum CRP concentrations were 
reliable prognostic markers in NSCLC. 
 
In patients with hyperfibrinogenemia, the hazard 
ratio (HR) was 1.44 (95% confidence interval 
[CI]: 1.09–2.13) for disease progression and 1.65 
(95% CI: 1.38–3.62) for death. Additionally, for 
patients with an elevated serum CRP level (> 20 
mg/L), the HR was 1.31 (95% CI: 1.05–2.2) for 
disease progression and 1.72 (95% CI: 1.20–




In our current investigation, elevated serum CRP 
and fibrinogen concentrations were positively 
associated with increased tumour diameter, sex, 
smoking status, histological type, pathologic 
tumour classification, and clinical stage. Patients 
with elevated serum CRP and fibrinogen 
concentrations were more likely to have 
incomplete tumour resection. In addition, 
elevated serum CRP and fibrinogen levels were 
determined to be independent predictors of 
worse patient outcomes. Thus, this study 
demonstrates an association between NSCLC, 
coagulation status, and physiological 
inflammation that suggests clinical benefits for 
selecting patients with NSCLC for surgery as well 
as their post-operative prognostic implications. 
 
The serum CRP level increases in several acute 
and chronic inflammatory disease conditions, 
including malignancy. The mechanism of the 
elevated serum CRP level in cancer patients is 
reportedly due to the production of pro-
inflammatory cytokines (i.e., IL-1, IL-2, TNF-α, 
and IFN-γ) involved in carcinogenesis [7,1919]. 
In the present investigation, sex, smoking, 
histological type, cancer stage classification, and 
clinical stage were all positively correlated with a 
higher serum CRP concentration, and 
Spearman’s correlation showed a strong positive 
association between maximum pathological 
cancer dimension and serum CRP level. These 
observations are consistent with previous studies 
of NSCLC and other malignancies, and they 
suggest that a greater cancer cell burden is more 
likely to augment the production of inflammatory 
cytokines and therefore higher serum levels of 
CRP [19].     
 
With the enhanced proliferation of tumour cells 
and their interactions with the stroma and other 
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supportive tissues that mediate tumour growth, 
there is increased expression of fibrinolytic and 
procoagulant factors that are generally lacking in 
normal stroma cells [20]. Furthermore, 
substantial amounts of fibrin and fibrinogen are 
deposited around solid tumours, implying that 
fibrinogen induces the development of the 
tumour stroma [14,20]. Additionally, fibrinogen-
mediated cellular interactions play a role in cell 
proliferation, cell migration, apoptosis, 
inflammatory factor production, and angiogenesis 
[14,20,21]. Moreover, the development of a 
platelet-fibrin-tumour cell promotes endothelial 
adhesion, as well as increased attachment; 
therefore, fibrinogen forms a layer on the surface 
of cancer cells to aid in the attachment of growth 
factors and induce tumour cell dispersion and 
metastasis [22]. Moreover, the fibrinogen coating 
may result in the protection of cancer cells from 
immune surveillance and extend malignant cell 
survival [21,22]. These observations are 
important provided the findings of this study and 
other investigations that showed a positive 
correlation between fibrinogen concentration with 
pathological tumour phase and primary tumour 
diameter but not with the pathological N stage 
[14].  
 
In this study, the rate of partial/incomplete 
resection was higher in patients with elevated 
serum CRP and plasma fibrinogen levels, 
demonstrating a relationship between these 
biomarkers and tumour malignancy. This may be 
useful for screening patients who can benefit 
from surgery. Furthermore, it may aid in 
identifying subpopulations of NSCLC patients 
who require a detailed evaluation for pre-
operative chemotherapy to reduce tumour size. 
Unlike this study, a previous study did not 
demonstrate significant findings between 
incomplete resection with serum CRP, plasma 
fibrinogen, or both biomarkers, although a trend 
towards a higher rate of incomplete resection 
was observed with increasing levels of these 
biomarkers. The major difference in these 
findings is that the previous study used higher 
cut-off levels for fibrinogen (> 5 g/L) and CRP (> 
40 mg/L) to demonstrate increased levels of 
these biomarkers relative to the current study 
[14].   
 
Plasma fibrinogen and serum CRP 
concentrations were markedly correlated with 
patient outcomes. Multivariate calculations 
determined by the Cox proportional hazards 
model demonstrated that increased 
concentrations of CRP and fibrinogen were 
independent predictors of poor OS and PFS. The 
present study also suggests a stage-dependent 
relationship between these pre-operative 
biomarkers and survival. Our results are 
consistent with those from earlier investigations 
and a systematic review that revealed increased 
serum CRP concentration as a poor prognostic 
indicator in patients with NSCLC [13–15]. In 
addition, our findings agree with recent studies 
indicating plasma fibrinogen level as a new 
reliable prognostic indicator for PFS and OS in 
NSCLC [18,19,22]. 
 
Limitations of the study 
 
Although the present study contributes 
significantly to our knowledge of NSCLC 
biomarkers, it has its own limitations, including a 
limited sample size. It was also conducted only at 




Serum CRP and plasma fibrinogen 
concentrations were elevated in patients with 
NSCLC and correlated with tumour size. Pre-
operative levels of serum CRP and plasma 
fibrinogen may serve as additional indicators of 
tumour resectability, wherein a high tumour 
resection rate is possible in patients with 
favourable pre-operative levels of these 
biomarkers. Elevated levels of these biomarkers 
in the pre-operative period are poor prognostic 
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